Search results
Showing 1 to 15 of 26 results for etoposide
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.
Evidence-based recommendations on serplulimab (Hetronifly) with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer in adults.
Show all sections
Evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer in adults.
Brentuximab vedotin in combination for untreated advanced classical Hodgkin lymphoma [ID6437]
In development Reference number: GID-TA11516 Expected publication date: 06 May 2027
In development Reference number: GID-TA11613 Expected publication date: TBC
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards
Awaiting development Reference number: GID-TA11094 Expected publication date: TBC
Evidence-based recommendations on durvalumab (Imfinzi) for treating limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults.
Show all sections
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)
Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults.
Show all sections
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)
Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.
Discontinued Reference number: GID-TA10413
Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)
Evidence-based recommendations on rituximab for the first-line treatment of stage III–IV follicular lymphoma.
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.
Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.